<DOC>
	<DOCNO>NCT00476944</DOCNO>
	<brief_summary>The purpose study compare rate vascular related complication patient undergo percutaneous coronary intervention assign one two arm : 1 ) bivalirudin + provisional Gp IIB/IIIA use versus 2 ) heparin + Gp IIB/IIIA ( eptifibatide ( Integrilin® ) ) use .</brief_summary>
	<brief_title>Comparing Bivalirudin Versus Heparin/ GP IIB/IIA Patients Undergoing PCI</brief_title>
	<detailed_description>Anti-thrombotic therapy enhance safety percutaneous coronary intervention ( PCI ) . In addition aspirin , heparin platelet glycoprotein ( Gp ) IIB/IIIA receptor inhibition use reference strategy reduce incidence ischemic complication coronary intervention 1 . However , success strategy limit increase bleeding risk , prolonged drug infusion ( 12 hour ) , patient inconvenience ( lie flat hour blood coagulation becomes normal sheath safely remove ) . Peri-procedural bleeding due vascular complication one frequent complication PCI associate adverse event 2 . Newer anti-thrombotic strategy may improve outcome PCI . The efficacy direct thrombin inhibitor bivalirudin ( Angiomax™ ) investigate randomize controlled clinical trial replacement strategy heparin/Gp IIB/IIIA inhibition patient undergoing coronary intervention . The REPLACE-2 study , randomized 6000 patient find short long-term clinical outcome bivalirudin effective heparin/Gp IIB/IIIA inhibition combination evidence significantly less major minor bleed 3 , 4 . This lead approval 0.75 mg/kg/1.75 mg/kg/hr dose Angiomax® Food Drug Administration use anticoagulant patient unstable angina undergoing PCI . It routinely accept early sheath removal PCI reduce femoral access site complication lead early ambulation , early discharge , improve patient satisfaction 5 . Heparin-based anticoagulation require monitor coagulation status determine readiness sheath removal lack predictable duration anticoagulation heparin . Because clearance bivalirudin occur mostly proteolytic cleavage thrombin , drug predictable pharmacokinetics exhibit linear dose relationship respect plasma concentration coagulation assay endpoint 6 . Preliminary study indicate sheath removal 2 hour cessation bivalirudin without coagulation monitoring safe 5 . While REPLACE-2 suggest catheterization relate vascular complication decrease bivalirudin , specific data endpoint others time ambulation time discharge collect blinded nature trial . Currently rate vascular complication MGH patient undergo PCI 4.0 % significantly exceed national rate 1.9 % ( 95 % CI 1.1 3.2 ) 7 . We conduct randomized clinical trial patient undergo PCI compare rate vascular related complication patient assign one two arm : 1 ) bivalirudin + provisional Gp IIB/IIIA use versus 2 ) heparin + Gp IIB/IIIA ( eptifibatide ( Integrilin® ) ) use . The primary endpoint composite vascular relate groin complication ( MAVE-major adverse vascular endpoint define next section ) . Secondary endpoint 1 ) time sheath pull ; 2 ) time ambulation ; 3 ) occurrence major minor bleed peri-catheterization .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patients must meet ALL follow criterion : The patient must &gt; 18 year age Patients must refer percutaneous coronary intervention ( PCI ) Diagnosis angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) OR unstable angina pectoris ( Braunwald Classification B &amp; C , IIIIII ) OR patient document silent ischemia ; Treatment lesion native coronary vessel bypass graft require angioplasty stenting . Patient willing comply specify followup evaluation ; Patient must provide write informed consent prior procedure use form approve local Institutional Review Board . Patients exclude ANY follow condition apply : Patient experience STsegment elevation myocardial infarction within precede 24 hour . Active internal bleeding bleed diathesis , surgery , trauma , gastrointestinal genitourinary tract bleed within past 6 week ; prior intracranial bleeding ; platelet count &lt; 100,000 Woman childbearing potential unless demonstrate negative pregnancy test End Stage Renal Disease require hemodialysis Recipient heart transplant ; Current treatment 1 ) intravenous unfractionated heparin treatment low molecular weight heparin within past 8 hour ; 2 ) bivalirudin ; 3 ) abciximab ; 4 ) eptifibatide ; tirofiban Ongoing need warfarin heparin therapy Known allergy aspirin , clopidogrel bisulfate ( Plavix® ) and/or heparin ; Any significant medical condition investigator ’ opinion may interfere patient ’ optimal participation study ; Currently participate investigational drug another device study ; Any contraindication glycoprotein IIb/IIIa inhibitor ( eptifibatide ( Integrilin® ) ) bivalirudin therapy ; Chronic relapse/remitting hemolytic condition precatheterization hematocrit &lt; 30 mg/dl Unprotected leave main coronary disease &gt; 50 % stenosis ; Platelet count &lt; 150,000</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>CAD</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Angiomax</keyword>
	<keyword>Bivalirudin</keyword>
	<keyword>PCI</keyword>
	<keyword>MAVE</keyword>
	<keyword>Heparin</keyword>
</DOC>